The Food and Drug Administration (FDA) has announced the accelerated approval of enfuvirtide (FuzeonTM, Roche) for use with other anti-HIV medications in adults and children ages six years and older with advanced human immunodeficiency virus (HIV) infection. Enfuvirtide is the first in a new class of medications called fusion inhibitors, which interfere with the fusion of viral and cellular membranes, thus hindering the entry of HIV-1 into cells.
Raltegravir tablets (Isentress, Merck) have been approved for the treatment of human immunodeficiency virus drug (HIV)-1 infection, in combination with other anti-retroviral agents, in patients who have received other therapies and who have evidence of viral replication and HIV-1 strains that are resistant to multiple antiretroviral agents.
Alcohol, race, and ethnicity all play complicated roles in lipid-profile changes in patients taking highly active antiretroviral therapy (HAART), according to researchers from Florida International University in Miami. HAART is already known to cause dyslipidemia in 40% to 80% of patients.
A longitudinal study of 88 “hazardous” and 76 “nonhazardous” drinkers reveals some differences that underscore the importance of tailoring treatment.
